Acute to Chronic Strategic opportunities exist in expanding TheraSkin and TheraGauze into clinics treating chronic wounds such as diabetic foot ulcers, venous stasis ulcers, and pressure injuries, leveraging CMS pass-through status to drive reimbursement and increase adoption.

Regenerative Market Position Solsys Medical as a regenerative medicine enabler by highlighting TheraSkin as a cellular active therapy and partnering with wound care centers and hospitals pursuing regenerative solutions to accelerate wound healing and reduce complications.

Regulatory Edge Capitalize on CMS pass-through status and FDA HCT/P homologous use designation to craft payer-focused value propositions, illustrating faster reimbursement timelines and broader market access for wound care products.

Distribution Leverage Target networks and distributors in the regenerative space, as well as high-volume wound care facilities, by offering bundled solutions comprising TheraSkin and TheraGauze to simplify logistics and improve outcomes.

Scale Readiness With a mid-size employee base and prior acquisition by Misonix, pursue partnerships with larger medtech players for co-commercialization or revenue-sharing arrangements to scale reach and accelerate market penetration.